COVID-19: Vaccines and Therapeutics
As part of AHA’s Joining Hands for Greater Impact series, Priya Bathija, AHA vice president of strategic initiatives, speaks with Rita Carreon, vice president for health at UnidosUS, about how to overcome barriers to vaccine confidence and access in the Latino community.
Pfizer asked the Food and Drug Administration to authorize for emergency use two 3-microgram doses of its COVID-19 vaccine for children aged 6 months through 4.
Once the COVID-19 omicron variant became prominent through Jan. 8, unvaccinated adults in Los Angeles County had a 3.6 times higher SARS-CoV-2 infection rate and 23 times higher hospitalization rate than adults who had received a COVID-19 vaccine booster, the Centers for Disease Control and…
As part of AHA’s Joining Hands for Greater Impact series, Julia Resnick, AHA director of strategic initiatives, speaks with Lydia Isaac, vice president for health equity and policy at the National Urban League, about vaccine hesitancy among parents and the importance of clear communication and…
The Food and Drug Administration granted full approval to the Moderna COVID-19 vaccine for individuals age 18 and older.
Eligibility for the COVID-19 vaccine has expanded to children, yet families continue to have questions about how to best keep their children safe and healthy. In this new podcast series, Joining Hands to Build Pediatric COVID-19 Vaccine Confidence, we are speaking with leaders from three national…
Findings suggest that access and other social barriers may be greater contributors to the gaps in vaccination rates.
After being hospitalized for COVID-19, an Oregon man describes his yearlong journey recovering from long-haul COVID, encouraging others to stay healthy and get vaccinated.
Amid a resurgent COVID-19 and annual flu season, the AHA has released new resources that hospitals and health systems can use to encourage communities to stay healthy and protect themselves.
Based on recent data on omicron variant susceptibility to monoclonal antibodies, the Food and Drug Administration revised its emergency use authorizations for the combination therapies bamlanivimab and etesevimab and REGEN-COV (casirivimab and imdevimab) to exclude geographic regions where the…